ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ACAD vs AMLX // ALTMAN Z-SCORE & DEBT/EQUITY

ACADIA Pharmaceuticals Inc. (NASDAQ) VS. Amylyx Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ACAD 3 — AMLX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACAD VS. AMLX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ACAD AMLX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 91.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 7.90% -35.00% +42.90 ACAD /roic <GO>
EV/EBITDA & P/E Valuation 31.2x — — TIE /valuation <GO>
Free Cash Flow Yield 2.94% -3.43% +6.37 ACAD /fcf-yield <GO>
Operating Margin 9.80% — — TIE /operating-margins <GO>
Net Profit Margin 36.50% — — TIE /net-margins <GO>
Revenue Growth (YoY) 11.90% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE 6.26 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 3/9 +4.00 ACAD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.5 51.9 -6.37 AMLX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 8.5x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.58B $3.60B -$21.1M AMLX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ACAD REV AMLX REV ACAD GROSS % AMLX GROSS % ACAD FCF AMLX FCF
FY 2025 $1.07B $0 91.7% — $105.1M -$123.5M
FY 2024 $957.8M $87.4M 91.5% 93.2% $157.2M -$167.8M
FY 2023 $726.4M $380.8M — — $16.7M $11.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACAD // BETA —
AMLX // BETA —